Phase I Clinical Trial of Oral Curcumin

By Ricky A. Sharma, Stephanie A. Euden, Sharon L. Platton, Darren N. Cooke, A. Shafayat, Heather R. Hewitt, T. Marczylo, B. Morgan, D. Hemingway, S. Plummer and 3 more. Clinical Cancer Research, 2004

805 citations recorded by the source corpus.

Subfields: Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/ad8afbd462a1b49c7eaaed7f0e0670365cff11f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Subash C. Gupta
2. K. Harikumar
3. Bharat B. Aggarwal
4. Bokyung Sung
5. S. Prasad
6. Gautam Sethi
7. A. Tyagi

In Molecular Medicine

1. Bharat B. Aggarwal
2. Bokyung Sung
3. K. Harikumar
4. S. Prasad
5. Subash C. Gupta
6. D. Kalman
7. S. Hewlings
8. A. Tyagi

Citations in the corpus

• Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases (2008, background): “It was reported that a daily oral dose of 3.6g of curcumin results in detectable levels in colorectal tissue, which might be sufficient to exert pharmacological activity (Sharma et al., 2004).”
• Curcumin, a component of golden spice: from bedside to bench and back. (2014, background): “1 nmol/L after an hour of dosing (Sharma et al., 2004).”
• Curcumin: A Review of Its’ Effects on Human Health (2017, background): “6 g/day curcumin for one to four months reported nausea and diarrhea and an increase in serum alkaline phosphatase and lactate dehydrogenase contents [66].”
• Bioactivity of dietary polyphenols: The role of metabolites (2020, background): “…metabolites, summing almost 100% (Sharma et al. 2004); moreover, plasma levels of curcumin glucuronides are higher than those of sulfate conjugates (1.92:1) (Vareed et al. 2008), results which are consistent with the ones obtained in other clinical trials (Sharma et al. 2004; Kunati et al. 2018).”
• Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. (2007, background): “On the basis of the results from these studies, curcumin is currently in clinical trials for treatment of various cancers (16, 17 ) and for Alzheimer’s disease (18).”